Last reviewed · How we verify

Inmunotek S.L. — Portfolio Competitive Intelligence Brief

Inmunotek S.L. pipeline: 0 marketed, 0 filed, 3 Phase 3, 19 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 19 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bactek-R Bactek-R phase 3 Bacterial lysate immunotherapy Immunology / Respiratory
Biological vaccine Biological vaccine phase 3 Vaccine Immunology
MV140 MV140 phase 3 Bacterial lysate vaccine Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Beijing Minhai Biotechnology Co., Ltd · 1 shared drug class
  2. Bharat Biotech International Limited · 1 shared drug class
  3. BioNTech · 1 shared drug class
  4. Boryung Pharmaceutical Co., Ltd · 1 shared drug class
  5. CanSino Biologics Inc. · 1 shared drug class
  6. Centre for Infectious Disease Research in Zambia · 1 shared drug class
  7. Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno · 1 shared drug class
  8. Arcturus Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Inmunotek S.L.:

Cite this brief

Drug Landscape (2026). Inmunotek S.L. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/inmunotek-s-l. Accessed 2026-05-16.

Related